Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion

  • Dan Călugăru
  • Mihai Călugăru
Letter to the Editor

Dear Editor:

We want to address several challenges that have arisen from the study by Januschowski et al. [1], which can be specifically summarized below.

Some relevant data are missing from the study (Table 1).
Table 1

Missing data from the article by Januschowski et al. [1]


 Anatomical types of macular edema (cystic changes within neurosensory retina/subretinal fluid/mixed type) at presentation and at weeks 24 and 48

 Diagnostic criteria for ischemic CRVO

 Presence/absence of the relative afferent pupillary defects

 Retinal capillary dropouts (no or small and very limited/≥ 10 disc areas of nonperfusion)

 Cotton wool spots (rare/> 5)

 Clearly predefined retreatment criteria for reinjections

 Percentage of eyes considered “dry” on OCT as per criterion of CRT ≤ 250 μm for the Stratus OCT [2] and ≤ 315.2 μm for the Spectralis OCT [3] at weeks 24 and 48

 Proportion of the eyes with nonischemic occlusions converted to ischemic forms during the follow-up period

 Incidence of...


Bevacizumab Optical Coherence Tomography Diabetic Retinopathy Macular Edema Retinal Vein Occlusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Compliance with ethical standards


All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No financial disclosures. Both authors (D.C. and M.C.) were involved in design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript.

The authors have full control of the primary data and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data if requested.

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.


  1. 1.
    Januschowski K, Feltgen N, Pielen A et al (2016) Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. doi: 10.1007/s00417-016-3471-2 Google Scholar
  2. 2.
    Chan A, Duker JS, Ko TH, Fujimoto JG, Schuman JS (2006) Normal macular thickness measurements in healthy eyes using stratus optical coherence tomography. Arch Ophthalmol 124:193–198CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Gover S, Murthy RK, Brar VS, Chalam KV (2009) Normative data formacular thickness by high-definition spectral-domain optical coherence tomography (spectralis). Am J Ophthalmol 148:266–271CrossRefGoogle Scholar
  4. 4.
    Freund KB, Korobelnik JF, Deveny R et al (2015) Treat-and extend regimens with anti-VEGF agents in retinal diseases. Retina 35:1489–1506CrossRefPubMedGoogle Scholar
  5. 5.
    Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A (2012) Benefict of bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology 119:2587–2591CrossRefPubMedGoogle Scholar
  6. 6.
    Călugăru D, Călugăru M (2015) Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study. J Ocul Pharmacol Ther 31:78–86CrossRefPubMedGoogle Scholar
  7. 7.
    Călugăru D, Călugăru M (2016) Central retinal vein occlusion: modifying current treatment protocols. Eye (Lond) 30:1395–1396CrossRefGoogle Scholar
  8. 8.
    Călugăru D, Călugăru M (2016) Intravitreal aflibercept for macula oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab and ranibizumab. Eye (Lond) 30:766Google Scholar
  9. 9.
    Călugăru D, Călugăru M (2016) Retinal vein occlusion, from basics to the latest treatment. Retina 36:e112–e113CrossRefPubMedGoogle Scholar
  10. 10.
    Călugăru D, Călugăru M (2015) Therapies for macular edema associated with central retinal vein occlusions. Ophthalmology 122:e65–e66CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Department of OphthalmologyUniversity of Medicine Cluj-Napoca/RomaniaCluj-NapocaRomania

Personalised recommendations